Influence of the Implantation Site on the Sensitivity of Patient Pancreatic Tumor Xenografts to Apo2L/TRAIL Therapy
- 1 March 2014
- journal article
- research article
- Published by Ovid Technologies (Wolters Kluwer Health) in Pancreas
- Vol. 43 (2), 298-305
- https://doi.org/10.1097/mpa.0000000000000099
Abstract
Objectives We have previously demonstrated activity of Apo2L/TRAIL against patient pancreatic tumor xenografts. Here, we have examined the influence of the tumor implantation site on therapeutic response of orthotopic tumors and their metastases to Apo2L/TRAIL. Methods Sensitivity of 6 patient pancreatic tumor xenografts to Apo2L/TRAIL was determined in a subcutaneous model. To compare the response of orthotopic tumors, cells from subcutaneous xenografts were injected into the pancreas. Tumor growth was confirmed by histological examination of selected mice, and then treatment was started. When all control mice developed externally palpable tumors, the experiment was terminated, and pancreatic weights compared between control and treated groups. Magnetic resonance imaging was used to quantitate the response of orthotopic and metastatic tumors. Results The sensitivity to Apo2L/TRAIL observed in subcutaneous tumors was maintained in orthotopic tumors. Metastatic spread was observed with orthotopic tumor implantation. In an orthotopic model of a sensitive tumor, primary and metastatic tumor burden was significantly reduced, and median survival significantly extended by Apo2L/TRAIL therapy. Conclusions Our data provide evidence that the site of tumor engraftment does not alter the inherent sensitivity of patient xenografts to Apo2L/TRAIL, and these results highlight the potential of Apo2L/TRAIL therapy against primary and metastatic pancreatic cancer.Keywords
This publication has 37 references indexed in Scilit:
- Predictive in vivo animal models and translation to clinical trialsDrug Discovery Today, 2012
- Death Receptor Agonists as a Targeted Therapy for CancerClinical Cancer Research, 2010
- Establishment and characterization of patient tumor-derived head and neck squamous cell carcinoma xenograftsCancer Biology & Therapy, 2009
- Effective Treatment of Advanced Human Melanoma Metastasis in Immunodeficient Mice Using Combination Metronomic Chemotherapy RegimensClinical Cancer Research, 2009
- Mouse xenograft models vs GEM models for human cancer therapeuticsDisease Models & Mechanisms, 2008
- An In vivo Platform for Translational Drug Development in Pancreatic CancerClinical Cancer Research, 2006
- The anti-tumor effect of Apo2L/TRAIL on patient pancreatic adenocarcinomas grown as xenografts in SCID miceJournal of Translational Medicine, 2005
- Orthotopic Transplantation Models of Pancreatic Adenocarcinoma Derived From Cell Lines and Primary Tumors and Displaying Varying Metastatic ActivityPancreas, 2004
- Antimetastatic efficacy of adjuvant gemcitabine in a pancreatic cancer orthotopic modelClinical & Experimental Metastasis, 2000
- Growth and metastasis of surgical specimens of human breast carcinomas in SCID mice.1996